CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Clinical trials for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Custom-Made vaccine plus immunotherapy shows promise for advanced cancers
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps control t…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Hope for kidney transplant patients with advanced skin cancer: new drug combo aims to fight tumors without losing the donor kidney
Disease control Recruiting nowThis study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New combo therapy aims to shrink tumors in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests two drugs, cabozantinib and nivolumab, in people with advanced melanoma or head and neck cancer that has spread. The goal is to see if the combination can shrink or stabilize tumors, and whether certain biomarkers in the tumor can predict who responds best. About…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New drug combo trial hopes to tame advanced cancers
Disease control Recruiting nowThis early-phase study tests a new drug called IACS-6274, given alone or with other medicines, in people with advanced solid tumors (like certain melanomas, ovarian, or uterine cancers). The main goal is to find the safest dose and understand side effects. About 54 adults will ta…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC
-
Cancer care at home: a new study tests if shots are better than clinic visits
Symptom relief Recruiting nowThis study looks at whether giving the cancer drug nivolumab as a shot at home is as good as getting it in a clinic. It aims to reduce the time, cost, and stress of traveling for treatment. About 50 adults with various advanced cancers will try both settings and report which they…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 16, 2026 22:51 UTC
-
Can your social life help you beat Cancer's aftermath? new study investigates
Knowledge-focused Recruiting nowThis study looks at how personal relationships and physical activity influence the quality of life of young adults (ages 18-39) who have been diagnosed with cancer. Researchers will track 250 participants over time to see how social connections and exercise habits change and affe…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:52 UTC
-
Could a poop transplant fix cancer treatment side effects?
Knowledge-focused Recruiting nowThis study looks at how the bacteria in your gut might cause stomach issues like diarrhea and colitis when you take certain cancer drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung cancer, or g…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:08 UTC
-
Can t cell clues predict immunotherapy success?
Knowledge-focused Recruiting nowThis study looks at how T cells change in people with advanced melanoma, lung, or other cancers during anti-PD-1 immunotherapy. Researchers will measure specific markers in blood samples to see if they can predict treatment response or resistance. The goal is to understand why so…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:57 UTC